Vimarsana
Biggest News Aggregation in the World

Page 2 - Cendr Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cendr Platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cendr Platform Today - Breaking & Trending Today

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript - Vimarsana News

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript

Published: August 5, 2022

Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David...

Source: seekingalpha.com
Related Topics:
United StatesNew ZealandNew South WalesKumar RajaDavid MazzoJohn MendittoPete EnderlinJames NiscoCaladrius BiosciencesCompany ParticipantsCaladrius Biosciences IncNational HealthCorporate Communications At CaladriusIr Corporate CommunicationsUniversity Of SydneyExchange CommissionResearch Council Clinical Trial CenterJapanese PharmaceuticalsIntestinal Cancer Trials GroupDevices AgencyConference Call AugustCaladrius Bioscience Second QuarterBusiness Update ConferenceVice PresidentInvestor Relations
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology - Vimarsana News

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

Published: July 6, 2022

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 -- Caladrius Biosciences, Inc. , a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse... | July 6, 2022

Source: marketscreener.com
Related Topics:
Western AustraliaUnited StatesJohn MendittoDavid SlackCaladrius BiosciencesCaladrius Biosciences IncCorporate CommunicationsCend Therapeutics IncEuropean Society For Medical OncologyCend TherapeuticsLisata TherapeuticsLancet GastroenterologyAndrew DeanGod HospitalChief Operating OfficerMedical OncologyProgression Free SurvivalOverall SurvivalResponse RatePartial ResponseComplete ResponseObjective Response RateControl RateStable DiseaseExecutive Vice President